ACR President Carol A. Langford, MD, MPH, highlights the importance of research in the field and where to find resources and initiatives within the ACR to support, fund, inspire, and enhance innovation. For more on this important topic, see Dr. Langford’s column in the January issue of The Rheumatologist.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

Hit the Ground Running with New Insurance Subcommittee Chair Michael Feely, MD
Dr. Feely discusses his previous work with the College, his current work as a practicing rheumatologist and how he will lead continued advances on the insurance front.

RA: How High Is the Toll?
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.

President’s Corner: ACR Initiatives Support Research at Every Level
For me, few ACR events bring home our connection as a rheumatology community more than our annual meeting, ACR Convergence. In addition to its many important opportunities for networking and education, one aspect of the meeting that always inspires me is the research. Research represents one of the three priorities of my presidential term because…
A Look Back at 2024 Regulatory Developments
In 2024, key federal healthcare regulations and policy developments—related to health insurance, privacy protections, reimbursement, biosimilar use and more—shaped the landscape of the practice of rheumatology in several important ways.
Federally Funded Providers Must Provide Language Assistance Services by July 5
By July 5, all providers who participate in federally funded healthcare programs, including Medicare and Medicaid, must provide language assistance programs for patients to meet requirements of Section 1557 of the Affordable Care Act.

Youthful Exuberance: The Year in Review for Pediatric Rheumatology
WASHINGTON, D.C.—It is no small task to summarize an entire year’s worth of research accomplishments in any field of medicine, let alone one as complex as rheumatology. At ACR Convergence 2024, the Pediatric Year in Review not only provided a thoughtful summary, but also grouped advances along several different themes. Immune Health & More Jessica…

Are You an Active Ally?
“What we’re after here is something called active allyship,” said Dr. Dwinita Mosby Tyler, CEO and founder of The Equity Project in her keynote address at ACR Convergence 2024. “It’s where you witness something that might be an injustice or you might see a disparity, and you don’t just talk about it, you research it; you do something about it.”
Voice of Rheumatology Coalition Meeting: Enhancing Collaboration
The Voice of Rheumatology (VOR) Coalition convened last month at ACR Convergence 2024 in Washington, D.C., to discuss the pressing federal and state legislative priorities that will affect both the practice of rheumatology and patient care in the year ahead. The Coalition, composed of leading rheumatology professional societies and patient advocacy groups, gathered to examine…
Telemedicine Flexibilities for Controlled Substance Prescriptions Extended Through 2025
A third extension of telemedicine flexibilities will continue to allow prescription of controlled substances via telemedicine without an in-person visit through the end of 2025.
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 250
- Next Page »
